representative work

Havn Life Sciences Completes $11.5 Million Bought Deal Financing


On January 7, 2021, Havn Life Sciences Inc. completed a bought deal public offering of 10,747,900 units at a price of $1.07 per unit for gross proceeds of approximately $11.5 million, which includes the exercise in full of the underwriters’ over-allotment option.

Each unit consists of one common share of Havn and one common share purchase warrant. Each warrant entitles the holder thereof to purchase one common share at an exercise price of $1.34 for a period of 36 months.

Cassels acted for Havn.

RELATED EXPERTISE: Securities | Taxation